Fibrin Sealants and Axillary Lymphatic Morbidity: A Systematic Review and Meta-Analysis of 23 Clinical Randomized Trials.
axillary lymphadenectomy
breast cancer
fibrin sealant
lymphatic morbidity
lymphocele
Journal
Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829
Informations de publication
Date de publication:
24 04 2021
24 04 2021
Historique:
received:
10
01
2021
revised:
11
04
2021
accepted:
21
04
2021
entrez:
30
4
2021
pubmed:
1
5
2021
medline:
1
5
2021
Statut:
epublish
Résumé
use of fibrin sealants following pelvic, paraaortic, and inguinal lymphadenectomy may reduce lymphatic morbidity. The aim of this meta-analysis is to evaluate if this finding applies to the axillary lymphadenectomy. randomized trials evaluating the efficacy of fibrin sealants in reducing axillary lymphatic complications were included. Lymphocele, drainage output, surgical-site complications, and hospital stay were considered as outcomes. twenty-three randomized studies, including patients undergoing axillary lymphadenectomy for breast cancer, melanoma, and Hodgkin's disease, were included. Fibrin sealants did not affect axillary lymphocele incidence nor the surgical site complications. Drainage output, days with drainage, and hospital stay were reduced when fibrin sealants were applied ( fibrin sealants after axillary dissection reduce the total axillary drainage output, the duration of drainage, and the hospital stay. No effects on the incidence of postoperative lymphocele and surgical site complications rate are found.
Sections du résumé
BACKGROUND
use of fibrin sealants following pelvic, paraaortic, and inguinal lymphadenectomy may reduce lymphatic morbidity. The aim of this meta-analysis is to evaluate if this finding applies to the axillary lymphadenectomy.
METHODS
randomized trials evaluating the efficacy of fibrin sealants in reducing axillary lymphatic complications were included. Lymphocele, drainage output, surgical-site complications, and hospital stay were considered as outcomes.
RESULTS
twenty-three randomized studies, including patients undergoing axillary lymphadenectomy for breast cancer, melanoma, and Hodgkin's disease, were included. Fibrin sealants did not affect axillary lymphocele incidence nor the surgical site complications. Drainage output, days with drainage, and hospital stay were reduced when fibrin sealants were applied (
CONCLUSION
fibrin sealants after axillary dissection reduce the total axillary drainage output, the duration of drainage, and the hospital stay. No effects on the incidence of postoperative lymphocele and surgical site complications rate are found.
Identifiants
pubmed: 33923153
pii: cancers13092056
doi: 10.3390/cancers13092056
pmc: PMC8123055
pii:
doi:
Types de publication
Journal Article
Review
Langues
eng
Références
Aesthet Surg J. 2013 May;33(4):487-96
pubmed: 23563904
J Surg Oncol. 2010 Jun 1;101(7):600-3
pubmed: 20461767
Eur Surg Res. 1995;27(5):346-52
pubmed: 7589007
Int J Gynecol Cancer. 2017 Jul;27(6):1283-1292
pubmed: 28640177
World J Surg Oncol. 2007 Sep 23;5:104
pubmed: 17888182
Am J Surg. 2008 Aug;196(2):170-4
pubmed: 18639659
Ann Surg Oncol. 2018 Sep;25(9):2632-2640
pubmed: 29948418
Breast J. 2003 Sep-Oct;9(5):393-6
pubmed: 12968960
Eur J Surg. 1993 May;159(5):263-5
pubmed: 8103359
Anticancer Res. 1995 Nov-Dec;15(6B):2843-5
pubmed: 8669876
BMC Surg. 2019 Apr 24;18(Suppl 1):125
pubmed: 31074399
Breast. 2009 Apr;18(2):109-14
pubmed: 19289285
Breast J. 2003 Sep-Oct;9(5):385-8
pubmed: 12968958
Breast Cancer Res Treat. 2005 Apr;90(3):263-71
pubmed: 15830140
Microsurgery. 2011 Jan;31(1):18-25
pubmed: 20878653
Int J Breast Cancer. 2012;2012:643132
pubmed: 23008776
Ann Ital Chir. 2014 Jan-Feb;85(1):88-92
pubmed: 23080086
Breast J. 2019 Nov;25(6):1090-1096
pubmed: 31338929
Med Oncol. 2011 Dec;28 Suppl 1:S22-30
pubmed: 20827578
J Breast Cancer. 2012 Dec;15(4):373-80
pubmed: 23346164
Eur Surg Res. 1998;30(6):439-43
pubmed: 9838238
Br J Surg. 2011 Jul;98(7):918-24
pubmed: 21456091
J Natl Cancer Inst. 2006 May 3;98(9):599-609
pubmed: 16670385
Clin Breast Cancer. 2017 Jul;17(4):293-297
pubmed: 28161131
Lancet Oncol. 2018 Oct;19(10):1385-1393
pubmed: 30196031
Ann Plast Surg. 2020 Jan;84(1S Suppl 1):S89-S93
pubmed: 31833893
Clin Breast Cancer. 2018 Oct;18(5):e1023-e1026
pubmed: 29754846
Breast Cancer Res Treat. 2001 May;67(1):9-14
pubmed: 11518470
Eur J Surg Oncol. 2011 Oct;37(10):829-35
pubmed: 21849243
J Korean Med Sci. 2009 Feb;24(1):92-6
pubmed: 19270819
Cir Cir. 2005 Sep-Oct;73(5):345-50
pubmed: 16336797
Am J Surg. 2014 Nov;208(5):824-830
pubmed: 24881016
PLoS One. 2018 Jan 5;13(1):e0189176
pubmed: 29304140
Int J Surg. 2014 Nov;12(11):1210-5
pubmed: 25462702
J Urol. 2009 Nov;182(5):2285-90
pubmed: 19762048
World J Surg Oncol. 2004 Dec 09;2:44
pubmed: 15588301
World J Surg. 2008 Jul;32(7):1450-5
pubmed: 18373121
J Am Coll Surg. 2001 May;192(5):591-9
pubmed: 11333096
Surg J (N Y). 2017 Apr 07;3(2):e69-e74
pubmed: 28825024
Ann Surg Oncol. 2011 Dec;18 Suppl 3:S292-3; author reply S294
pubmed: 21213055
Macromol Biosci. 2020 Jan;20(1):e1900283
pubmed: 31769933
Gynecol Obstet Fertil. 2013 Oct;41(10):583-7
pubmed: 24139816
Am Surg. 2000 May;66(5):444-50; discussion 450-1
pubmed: 10824744
J Surg Oncol. 2016 Sep;114(4):423-7
pubmed: 27338717
Br J Surg. 2004 Jan;91(1):54-60
pubmed: 14716794
Am J Surg. 1999 Jun;177(6):450-3
pubmed: 10414691
G Chir. 2009 Jun-Jul;30(6-7):306-10
pubmed: 19580713
Clin Breast Cancer. 2017 Jul;17(4):316-321
pubmed: 28202253
Eur J Surg Oncol. 2012 Oct;38(10):902-9
pubmed: 22703757
Ann Surg Oncol. 2010 Sep;17(9):2452-8
pubmed: 20379783
Curr Opin Obstet Gynecol. 2020 Feb;32(1):91-99
pubmed: 31833973
Cochrane Database Syst Rev. 2013 May 31;(5):CD009557
pubmed: 23728694
BMC Surg. 2013;13 Suppl 2:S8
pubmed: 24266959